Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

Exclusion Criteria

• •Nonmyeloablative preparative regimen
• •Participation in an investigational study that has acute GVHD as the primary endpoint
• •The allogeneic PBSC donor has a contraindication to statin treatment
• •DONOR: Age \< 18 years
• •DONOR: Active liver disease (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\] levels \> 2 times the upper limit of normal \[ULN\])
• •DONOR: History of myopathy
• •DONOR: Hypersensitivity to atorvastatin
• •DONOR: Pregnancy
• •DONOR: Nursing mother
• •DONOR: Current serious systemic illness
• •DONOR: Concurrent treatment with strong inhibitors of hepatic cytochrome P450 (CYP) 3A4 (i.e. clarithromycin, erythromycin, protease inhibitors, azole antifungals)
• •DONOR: Current use of statin drug
• •DONOR: Failure to meet Fred Hutchinson Cancer Research Center (FHCRC) or local criteria for stem cell donation
• •DONOR: Total creatinine kinase \> 2 times the ULN